Are there new emerging drugs for ankylosing spondylitis or spondyloarthritis?

Bibliography

• Wendling D, Toussirot E. Anti-TNF-alpha therapy in ankylosing spondylitis. Expert Opin Pharmacother 2004;5(7):1497-507
   PubMed Web of Science ®Google Scholar
• McLeod C, Bagust A, Boland A, Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007;11(28):1-158
   Web of Science ®Google Scholar
• Emery P, Busquets-Perez N, Marzo-Ortega H. Emerging drugs for ankylosing spondylitis. Expert Opin Emerg Drugs 2013;18(1):71-86
   PubMed Web of Science ®Google Scholar
• Pham T, Bachelez H, Berthelot JM, TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 2011;78(Suppl 1):15-185
   PubMed Web of Science ®Google Scholar
• Wendling D, Prati C. Biologic agents for treating ankylosing spondylitis: beyond TNFα antagonists. Joint Bone Spine 2011;78(6):542-4
   PubMed Web of Science ®Google Scholar
• Chen J, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2006(4):CD004524
   Google Scholar
• Chen J, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005(2):CD004800
   Google Scholar
• van Denderen JC, van der Paardt M, Nurmohamed MT, Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis 2005;64(12):1761-4
   PubMed Web of Science ®Google Scholar
• Mulleman D, Lauféron F, Wendling D, Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. Arthritis Res Ther 2011;13(3):R82
   PubMedGoogle Scholar
• Song IH, Heldmann F, Rudwaleit M, Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011;70:1108-10
   PubMed Web of Science ®Google Scholar
• Lekpa FK, Farrenq V, Canouï-Poitrine F, Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition. Joint Bone Spine 2012;79:47-50
   PubMed Web of Science ®Google Scholar
• Song IH, Heldmann F, Rudwaleit M, Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 2010;62:1290-7
   PubMed Web of Science ®Google Scholar
• Wendling D, Dougados M, Berenbaum F, Rituximab Treatment for Spondyloarthritis. A Nationwide Series: data from the AIR Registry of the French Society of Rheumatology. J Rheumatol 2012; [Epub ahead of print]
   Web of Science ®Google Scholar
• Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005;64(2):296-8
   PubMed Web of Science ®Google Scholar
• Tan AL, Marzo-Ortega H, O'Connor P, Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 2004;63(9):1041-5
   PubMed Web of Science ®Google Scholar
• Wendling D. Interleukin-6 as a therapeutic target in spondylarthritis: comment on the article by Tanaka et al. Arthritis Care Res (Hoboken) 2010;62(5):745
   PubMed Web of Science ®Google Scholar
• Lekpa FK, Poulain C, Wendling D, Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? A multicentre retrospective observational study. Arthritis Res Ther 2012;14(2):R53
   PubMed Web of Science ®Google Scholar
• Sieper J, Porter-Brown B, Thompson L, Tocilizumab (tcz) is not effective for the treatment of ankylosing spondylitis (as): results of a phase 2, international, multicentre, randomised, double-blind, placebo-controlled trial[op0166]. Ann Rheum Dis 2012;71(Suppl 3):110
   Google Scholar
• Sieper J, Inman RD, Badalamenti S, Sarilumab for the treatment of ankylosing spondylitis: results of a phase 2, randomized. Double-blind, placebo-controlled, international study (align) [op0169]. Ann Rheum Dis 2012;71(Suppl 3):111
   Google Scholar
• Wendling D. IL-23 and IL-17 in ankylosing spondylitis. Rheumatol Int 2010;30(11):1547
   PubMed Web of Science ®Google Scholar
• Baeten D, Sieper J, Emery P, The anti-IL17A monoclonal antibody Secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Arthritis Rheum 2010;62:3840-1
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT01330901
   Google Scholar
• Poddubnyy D, Rudwaleit M, Haibel H, Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012;71(10):1616-22
   PubMed Web of Science ®Google Scholar
• Haroon N, Kim TH, Inman RD. NSAIDs and radiographic progression in ankylosing spondylitis Bagging big game with small arms? Ann Rheum Dis 2012;71(10):1593-5
   PubMed Web of Science ®Google Scholar
• Braem K, Lories RJ. Insights into the pathophysiology of ankylosing spondylitis: contributions from animal models. Joint Bone Spine 2012;79(3):243-8
   PubMed Web of Science ®Google Scholar
• Carter S, Braem K, Lories RJ. The role of bone morphogenetic proteins in ankylosing spondylitis. Ther Adv Musculoskelet Dis 2012;4(4):293-9
   Google Scholar
• Braun J, Sieper J, Zink A. The risks of smoking in patients with spondyloarthritides. Ann Rheum Dis 2012;71(6):791-2
   PubMed Web of Science ®Google Scholar
• Wendling D, Prati C, Goupille P, Mulleman D. Optimizing TNFα antagonist therapy in patients with spondyloarthritis: why and how? Joint Bone Spine 2011;78(3):225-7
   PubMed Web of Science ®Google Scholar